Axsome announces preliminary FY2024 revenue $385.2M; Auvelity $291.4M

Axsome Therapeutics, Inc.

2024-FY EPS reported -$5.99 revenue$385,693,000

Total product revenue Q4 $118.3M, full year $385.2M (unaudited preliminary).
Auvelity net product sales Q4 $92.6M, full year $291.4M.
Sunosi net product revenue Q4 $25.7M, full year $93.8M.
CEO cites positive Phase 3 results for AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy); regulatory filings planned in 2025.
Active launch preparations underway for AXS-07 (migraine), if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.